Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma

G. Schiller, R. Vescio, C. Freytes, G. Spitzer, M. Lee, C. H. Wu, J. Cao, J. C. Lee, A. Lichtenstein, M. Lill, R. Berenson, J. Berenson

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood progenitor cell transplants following myeloablative chemotherapy. A median of 4.1 x 106 CD34 cells/kg (range 1.2-30.7) were infused after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg); granulocyte-macrophage colony-stimulating factor was used until hematopoietic recovery. Median time to neutrophils > 0.5 x 109/l and platelets > 20 x 109/l were 12 days (range 10-16 and 8-184 days, respectively). Median follow-up of survivors from the time of transplantation is 33 months (range 7 to 44 months). Thirty-one patients are alive, 19 progression-free. Median progression-free survival is 14 months. Actuarial 3-year progression-free and overall survival are 29 ± 14% and 47 ± 17%. CD34-selection of peripheral blood progenitor cells provides effective hematopoietic support with significant progression-free and overall survival.

Original languageEnglish (US)
Pages (from-to)141-145
Number of pages5
JournalBone Marrow Transplantation
Volume21
Issue number2
StatePublished - Jan 2 1998

Fingerprint

Multiple Myeloma
Disease-Free Survival
Blood Cells
Stem Cells
Transplants
Busulfan
Granulocyte-Macrophage Colony-Stimulating Factor
Cyclophosphamide
Survivors
Neutrophils
Blood Platelets
Transplantation
Drug Therapy

Keywords

  • CD34-positive stem cells
  • Multiple myeloma
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Schiller, G., Vescio, R., Freytes, C., Spitzer, G., Lee, M., Wu, C. H., ... Berenson, J. (1998). Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplantation, 21(2), 141-145.

Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. / Schiller, G.; Vescio, R.; Freytes, C.; Spitzer, G.; Lee, M.; Wu, C. H.; Cao, J.; Lee, J. C.; Lichtenstein, A.; Lill, M.; Berenson, R.; Berenson, J.

In: Bone Marrow Transplantation, Vol. 21, No. 2, 02.01.1998, p. 141-145.

Research output: Contribution to journalArticle

Schiller, G, Vescio, R, Freytes, C, Spitzer, G, Lee, M, Wu, CH, Cao, J, Lee, JC, Lichtenstein, A, Lill, M, Berenson, R & Berenson, J 1998, 'Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma', Bone Marrow Transplantation, vol. 21, no. 2, pp. 141-145.
Schiller G, Vescio R, Freytes C, Spitzer G, Lee M, Wu CH et al. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplantation. 1998 Jan 2;21(2):141-145.
Schiller, G. ; Vescio, R. ; Freytes, C. ; Spitzer, G. ; Lee, M. ; Wu, C. H. ; Cao, J. ; Lee, J. C. ; Lichtenstein, A. ; Lill, M. ; Berenson, R. ; Berenson, J. / Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. In: Bone Marrow Transplantation. 1998 ; Vol. 21, No. 2. pp. 141-145.
@article{e90fc12d2e4c42cf94cd258cc8750ef5,
title = "Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma",
abstract = "Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood progenitor cell transplants following myeloablative chemotherapy. A median of 4.1 x 106 CD34 cells/kg (range 1.2-30.7) were infused after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg); granulocyte-macrophage colony-stimulating factor was used until hematopoietic recovery. Median time to neutrophils > 0.5 x 109/l and platelets > 20 x 109/l were 12 days (range 10-16 and 8-184 days, respectively). Median follow-up of survivors from the time of transplantation is 33 months (range 7 to 44 months). Thirty-one patients are alive, 19 progression-free. Median progression-free survival is 14 months. Actuarial 3-year progression-free and overall survival are 29 ± 14{\%} and 47 ± 17{\%}. CD34-selection of peripheral blood progenitor cells provides effective hematopoietic support with significant progression-free and overall survival.",
keywords = "CD34-positive stem cells, Multiple myeloma, Transplantation",
author = "G. Schiller and R. Vescio and C. Freytes and G. Spitzer and M. Lee and Wu, {C. H.} and J. Cao and Lee, {J. C.} and A. Lichtenstein and M. Lill and R. Berenson and J. Berenson",
year = "1998",
month = "1",
day = "2",
language = "English (US)",
volume = "21",
pages = "141--145",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma

AU - Schiller, G.

AU - Vescio, R.

AU - Freytes, C.

AU - Spitzer, G.

AU - Lee, M.

AU - Wu, C. H.

AU - Cao, J.

AU - Lee, J. C.

AU - Lichtenstein, A.

AU - Lill, M.

AU - Berenson, R.

AU - Berenson, J.

PY - 1998/1/2

Y1 - 1998/1/2

N2 - Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood progenitor cell transplants following myeloablative chemotherapy. A median of 4.1 x 106 CD34 cells/kg (range 1.2-30.7) were infused after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg); granulocyte-macrophage colony-stimulating factor was used until hematopoietic recovery. Median time to neutrophils > 0.5 x 109/l and platelets > 20 x 109/l were 12 days (range 10-16 and 8-184 days, respectively). Median follow-up of survivors from the time of transplantation is 33 months (range 7 to 44 months). Thirty-one patients are alive, 19 progression-free. Median progression-free survival is 14 months. Actuarial 3-year progression-free and overall survival are 29 ± 14% and 47 ± 17%. CD34-selection of peripheral blood progenitor cells provides effective hematopoietic support with significant progression-free and overall survival.

AB - Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood progenitor cell transplants following myeloablative chemotherapy. A median of 4.1 x 106 CD34 cells/kg (range 1.2-30.7) were infused after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg); granulocyte-macrophage colony-stimulating factor was used until hematopoietic recovery. Median time to neutrophils > 0.5 x 109/l and platelets > 20 x 109/l were 12 days (range 10-16 and 8-184 days, respectively). Median follow-up of survivors from the time of transplantation is 33 months (range 7 to 44 months). Thirty-one patients are alive, 19 progression-free. Median progression-free survival is 14 months. Actuarial 3-year progression-free and overall survival are 29 ± 14% and 47 ± 17%. CD34-selection of peripheral blood progenitor cells provides effective hematopoietic support with significant progression-free and overall survival.

KW - CD34-positive stem cells

KW - Multiple myeloma

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0031973764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031973764&partnerID=8YFLogxK

M3 - Article

C2 - 9489630

AN - SCOPUS:0031973764

VL - 21

SP - 141

EP - 145

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -